{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:39:48Z","timestamp":1788316788880,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T00:00:00Z","timestamp":1495152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["89\u201003\u201041\u201011192"],"award-info":[{"award-number":["89\u201003\u201041\u201011192"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the efficacy of intravenous high\u2010dose pulses of methylprednisolone (<jats:styled-content style=\"fixed-case\">IVPM<\/jats:styled-content>) for treatment of ocular involvement in Behcet's disease (<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In a double\u2010blind control study, we randomized <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> patients with posterior uveitis (<jats:styled-content style=\"fixed-case\">PU<\/jats:styled-content>) and\/or retinal vasculitis (<jats:styled-content style=\"fixed-case\">RV<\/jats:styled-content>) into two groups. They received either <jats:styled-content style=\"fixed-case\">IVPM<\/jats:styled-content> (1000 mg methylprednisolone) or placebo for 3 consecutive days. Both groups received combination therapy with <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> cyclophosphamide, azathioprine and prednisolone for 6 months. Visual acuity (<jats:styled-content style=\"fixed-case\">VA<\/jats:styled-content>), Disease Activity Index (<jats:styled-content style=\"fixed-case\">DAI<\/jats:styled-content>) based on the inflammatory state of each section of each eye, total inflammatory (<jats:styled-content style=\"fixed-case\">TIAI<\/jats:styled-content>) and adjusted <jats:styled-content style=\"fixed-case\">DAI<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">TADAI<\/jats:styled-content>) for each patient were calculated. The comparisons were done by paired <jats:italic>t\u2010<\/jats:italic> and Mann\u2013Whitney <jats:italic>U\u2010<\/jats:italic>test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen patients in each group completed the treatment. The mean <jats:styled-content style=\"fixed-case\">VA<\/jats:styled-content> improved from 0.5 to 0.8 (<jats:italic>P<\/jats:italic> &lt; 0.000001) for the study and from 0.6 to 0.7 (<jats:italic>P<\/jats:italic> &lt; 0.02) for the placebo group. The difference was significant (<jats:italic>P<\/jats:italic> = 0.01). The comparison showed no significant difference regarding <jats:styled-content style=\"fixed-case\">DAI<\/jats:styled-content> improvement in other items (<jats:italic>P<\/jats:italic> &gt; 0.2): <jats:styled-content style=\"fixed-case\">PU<\/jats:styled-content>, 1.9 to 0.5 (<jats:italic>P<\/jats:italic> &lt; 0.0006) versus 2.3 to 0.8 (<jats:italic>P<\/jats:italic> &lt; 0.0002); <jats:styled-content style=\"fixed-case\">RV<\/jats:styled-content>: 4.0 to 1.1 (<jats:italic>P<\/jats:italic> &lt; 0.0004) versus 3.1 to 1.1 (<jats:italic>P<\/jats:italic> &lt; 0.0005); <jats:styled-content style=\"fixed-case\">TIAI<\/jats:styled-content>: 23 to 5.7 (<jats:italic>P<\/jats:italic> &lt; 0.0002) versus 24.8 to 8.4 (<jats:italic>P<\/jats:italic> &lt; 0.003); <jats:styled-content style=\"fixed-case\">TADAI<\/jats:styled-content>: 24.1 to 7.3 (<jats:italic>P<\/jats:italic> &lt; 0.0002) versus 25.9 to 7.9 (<jats:italic>P<\/jats:italic> &lt; 0.004). We had one flare in the study versus seven in the placebo group (<jats:italic>P<\/jats:italic> &lt; 0.005).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adding high\u2010dose intravenous steroid pulse therapy to conventional combination therapy for severe ocular lesions of <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> may cause better improvement on <jats:styled-content style=\"fixed-case\">VA<\/jats:styled-content> and fewer flares during the first 6 months of treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13095","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T11:33:22Z","timestamp":1495193602000},"page":"1269-1276","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["High\u2010dose intravenous steroid pulse therapy in ocular involvement of Behcet's disease: a pilot double\u2010blind controlled study"],"prefix":"10.1111","volume":"20","author":[{"given":"Mastaneh","family":"Mohammadi","sequence":"first","affiliation":[{"name":"Behcet's Disease Unit Rheumatology Research Center Shariati Hospital Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1830-6203","authenticated-orcid":false,"given":"Farhad","family":"Shahram","sequence":"additional","affiliation":[{"name":"Behcet's Disease Unit Rheumatology Research Center Shariati Hospital Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hormoz","family":"Shams","sequence":"additional","affiliation":[{"name":"Behcet's Disease Unit Rheumatology Research Center Shariati Hospital Tehran Iran"},{"name":"Farabi Eye Hospital Tehran University of Medical Sciences Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoomeh","family":"Akhlaghi","sequence":"additional","affiliation":[{"name":"Behcet's Disease Unit Rheumatology Research Center Shariati Hospital Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farimah","family":"Ashofteh","sequence":"additional","affiliation":[{"name":"Behcet's Disease Unit Rheumatology Research Center Shariati Hospital Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereydoun","family":"Davatchi","sequence":"additional","affiliation":[{"name":"Behcet's Disease Unit Rheumatology Research Center Shariati Hospital Tehran Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02912462"},{"key":"e_1_2_9_3_1","first-page":"15","article-title":"The risk factors and causes for blindness in Behcet's disease","volume":"20","author":"Shams H","year":"2008","journal-title":"Iran J Ophthalmol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002013220501"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.5.521"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.70.8.589"},{"key":"e_1_2_9_7_1","first-page":"119","article-title":"Management of ocular manifestation of Behcet's disease outcome with cytotoxic drugs","volume":"8","author":"Davatchi F","year":"2005","journal-title":"Int J Rheum Dis"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-011-0120-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(99)80163-9"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12009-007-0018-5"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12107"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12248"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-009-0191-z"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080432"},{"key":"e_1_2_9_15_1","first-page":"95","article-title":"Intravenous corticosteroid megadose treatment in ocular Beh\u00e7et disease","volume":"262","author":"Postelmans L","year":"1996","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq366"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13095","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T01:37:02Z","timestamp":1696037822000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1111\/1756-185X.13095"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13095","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,19]]},"assertion":[{"value":"2017-05-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}